ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
ELITE PHARMACEUTICALS INC /NV/
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.25−0.00 (-1.37%)
Close on Oct 19, 2026
- Market cap
- $283.02M
- P/E (TTM)
- 5.0
- Dividend yield
- –
ELITE PHARMACEUTICALS INC /NV/ revenue by segment
By business segment
| Revenue | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbreviated New Drug Applications [Member] | – | – | – | – | $105.45M | $84.04M | $70.00M | $71.17M | $66.45M | $56.63M | $47.32M | $41.03M | – | – |
| New Drug Applications [Member] | – | – | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | – | – | – | – |
| Operating income | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Business Segment [Member] | – | – | $65.40M | $57.82M | $51.36M | $32.12M | $23.27M | $24.58M | $22.18M | $19.47M | $15.52M | $13.71M | – |
| Abbreviated New Drug Applications [Member] | – | – | $65.40M | $57.82M | $51.36M | $32.12M | $23.27M | $24.58M | $22.18M | $19.47M | $15.52M | $13.71M | – |
By product or service
| Revenue | TTM Q1 27 | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Licensing [Member] | $847.63K | $1.06M | $1.18M | $1.60M | $2.13M | $2.06M | $1.68M | $1.80M | $1.79M | $2.50M | – | – | 0.6% | -60.2% |
| Manufacturing [Member] | – | $147.81M | $138.94M | $121.29M | $103.32M | $81.99M | $68.32M | $69.37M | $64.66M | $54.12M | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Elite Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.